Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Las Vegas Sands Corp. (LVS) vs Nuwellis Inc (NUWE) Price & Performance

Las Vegas Sands Corp.Trade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Las Vegas Sands Corp. vs Nuwellis Inc — how do they compare? Las Vegas Sands Corp. trades at $45.51 (market cap $29.44B), while Nuwellis Inc trades at $1.43 (market cap $542.80K). The key difference: Las Vegas Sands Corp. is far larger — about 54237.3× Nuwellis Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

LVSNUWE
Market Cap
$29.44B$542.80K
Sector
Consumer CyclicalTechnology
52-Week High
$69.49$220.50
52-Week Low
$44.78$1.42
Enterprise Value
$41.33B-$1.27M
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Las Vegas Sands Corp.

LVS trades at $45.46, down 0.68% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates at $0.59 versus $0.757 expected, but revenue growth remains robust with 2025 revenue at $13.02B. Analyst consensus is strongly bullish with a $60.75 price target and no sell ratings among 49 analysts. Recent news highlights corporate responsibility efforts and operational achievements in Macao.

The outlook is supported by strong fundamentals including a 12.59% net income margin and positive cash flow trends, but risks include high debt levels and competitive pressures. Upside potential exists if earnings rebound in Q3, aligning with analyst optimism, though technical weakness near support at $44 requires monitoring for stability.

Nuwellis Inc

NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.

Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.

Returns comparison

Trailing returns across standard periods

About Las Vegas Sands Corp.

Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.

Read more on LVS

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE